Gene Set Signature of Reversal Reaction Type I in Leprosy Patients

English version České info

Leprosy reversal reactions type 1 (T1R) are acute immune episodes that affect a subset of leprosy patients and remain a major cause of nerve damage. Little is known about the relative importance of innate versus environmental factors in the pathogenesis of T1R. In a retrospective design, we evaluated innate differences in response to Mycobacterium leprae between healthy individuals and former leprosy patients affected or free of T1R by analyzing the transcriptome response of whole blood to M. leprae sonicate. Validation of results was conducted in a subsequent prospective study. We observed the differential expression of 581 genes upon exposure of whole blood to M. leprae sonicate in the retrospective study. We defined a 44 T1R gene set signature of differentially regulated genes. The majority of the T1R set genes were represented by three functional groups: i) pro-inflammatory regulators; ii) arachidonic acid metabolism mediators; and iii) regulators of anti-inflammation. The validity of the T1R gene set signature was replicated in the prospective arm of the study. The T1R genetic signature encompasses genes encoding pro -⁠ and anti-inflammatory mediators of innate immunity. This suggests an innate defect in the regulation of the inflammatory response to M. leprae antigens. The identified T1R gene set represents a critical first step towards a genetic profile of leprosy patients who are at increased risk of T1R and concomitant nerve damage.

Vyšlo v časopise: Gene Set Signature of Reversal Reaction Type I in Leprosy Patients. PLoS Genet 9(7): e32767. doi:10.1371/journal.pgen.1003624
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003624

Souhrn

Zdroje

1. WHO (2010) Global leprosy situation, 2010. Wkly Epidemiol Rec 85 : 337–348.

2. BrittonWJ, LockwoodDN (2004) Leprosy. Lancet 363 : 1209–1219.

3. ScollardDM, AdamsLB, GillisTP, KrahenbuhlJL, TrumanRW, et al. (2006) The continuing challenges of leprosy. Clin Microbiol Rev 19 : 338–381.

4. RidleyDS, JoplingWH (1966) Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 34 : 255–273.

5. FavaV, OrlovaM, CobatA, AlcaisA, MiraM, et al. (2012) Genetics of leprosy reactions: an overview. Mem Inst Oswaldo Cruz 107 ((Suppl. I)) 132–42.

6. WalkerSL, LockwoodDN (2007) Leprosy. Clin Dermatol 25 : 165–172.

7. KumarB, DograS, KaurI (2004) Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int J Lepr Other Mycobact Dis 72 : 125–133.

8. RanqueB, NguyenVT, VuHT, NguyenTH, NguyenNB, et al. (2007) Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy. Clin Infect Dis 44 : 33–40.

9. LittleD, Khanolkar-YoungS, CoulthartA, SuneethaS, LockwoodDN (2001) Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infect Immun 69 : 3413–3417.

10. RoseP, WatersMF (1991) Reversal reactions in leprosy and their management. Lepr Rev 62 : 113–121.

11. VerhagenCE, WierengaEA, BuffingAA, ChandMA, FaberWR, et al. (1997) Reversal reaction in borderline leprosy is associated with a polarized shift to type 1-like Mycobacterium leprae T cell reactivity in lesional skin: a follow-up study. J Immunol 159 : 4474–4483.

12. StefaniMM, MartelliCM, GillisTP, KrahenbuhlJL (2003) In situ type 1 cytokine gene expression and mechanisms associated with early leprosy progression. J Infect Dis 188 : 1024–1031.

13. MoraesMO, SarnoEN, AlmeidaAS, SaraivaBC, NeryJA, et al. (1999) Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL). Scand J Immunol 50 : 541–549.

14. MoraesMO, SampaioEP, NeryJA, SaraivaBC, AlvarengaFB, et al. (2001) Sequential erythema nodosum leprosum and reversal reaction with similar lesional cytokine mRNA patterns in a borderline leprosy patient. Br J Dermatol 144 : 175–181.

15. Khanolkar-YoungS, RaymentN, BrickellPM, KatzDR, VinayakumarS, et al. (1995) Tumour necrosis factor-alpha (TNF-alpha) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol 99 : 196–202.

16. Becx-BleuminkM, BerheD (1992) Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis 60 : 173–184.

17. van BrakelWH, KhawasIB, LucasSB (1994) Reactions in leprosy: an epidemiological study of 386 patients in west Nepal. Lepr Rev 65 : 190–203.

18. SchreuderPA (1998) The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987–1995 [correction of 1978–1995]. II. Reactions. Int J Lepr Other Mycobact Dis 66 : 159–169.

19. SharmaN, KoranneRV, MendirattaV, SharmaRC (2004) A study of leprosy reactions in a tertiary hospital in Delhi. J Dermatol 31 : 898–903.

20. HuangdW, ShermanBT, LempickiRA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4 : 44–57.

21. DennisGJr, ShermanBT, HosackDA, YangJ, GaoW, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: R60.1–R60.11.

22. AshburnerM, BallCA, BlakeJA, BotsteinD, ButlerH, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25 : 25–29.

23. LeeHK, BraynenW, KeshavK, PavlidisP (2005) ErmineJ: tool for functional analysis of gene expression data sets. BMC Bioinformatics 6 : 269–276.

24. GillisJ, MistryM, PavlidisP (2010) Gene function analysis in complex data sets using ErmineJ. Nat Protoc 5 : 1148–1159.

25. BrittonWJ (1998) The management of leprosy reversal reactions. Lepr Rev 69 : 225–234.

26. WalkerSL, LockwoodDN (2008) Leprosy type 1 (reversal) reactions and their management. Lepr Rev 79 : 372–386.

27. CooperCL, MuellerC, SinchaisriTA, PirmezC, ChanJ, et al. (1989) Analysis of naturally occurring delayed-type hypersensitivity reactions in leprosy by in situ hybridization. J Exp Med 169 : 1565–1581.

28. KirkaldyAA, MusondaAC, Khanolkhar-YoungS, SuneethaS, LockwoodDN (2003) Expression of CC and CXC chemokines and chemokine receptors in human leprosy skin lesions. Clin Exp Immunol 134 : 447–453.

29. PesceC, GrattarolaM, MeniniS, FialloP (2006) Cyclooxygenase 2 expression in vessels and nerves in reversal reaction leprosy. Am J Trop Med Hyg 74 : 1076–1077.

30. MindrescuC, LeJ, WisniewskiHG, VilcekJ (2005) Up-regulation of cyclooxygenase-2 expression by TSG-6 protein in macrophage cell line. Biochem Biophys Res Commun 330 : 737–745.

31. KozakKR, RowlinsonSW, MarnettLJ (2000) Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem 275 : 33744–33749.

32. FournierT, MedjoubiN, PorquetD (2000) Alpha-1-acid glycoprotein. Biochim Biophys Acta 1482 : 157–171.

33. GuptaN, ShankernarayanNP, DharmalingamK (2010) alpha1-acid glycoprotein as a putative biomarker for monitoring the development of the type II reactional stage of leprosy. J Med Microbiol 59 : 400–407.

34. KupcovaV, TureckyL, DetkovaZ, PrikazskaM, KeleovaA (2003) Changes in acute phase proteins after anti-tumor necrosis factor antibody (infliximab) treatment in patients with Crohn's disease. Physiol Res 52 : 89–93.

35. SallenaveJM (2000) The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease. Respir Res 1 : 87–92.

36. HenriksenPA, HittM, XingZ, WangJ, HaslettC, et al. (2004) Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J Immunol 172 : 4535–4544.

37. ThomasSR, StockerR (1999) Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep 4 : 199–220.

38. BelladonnaML, GrohmannU, GuidettiP, VolpiC, BianchiR, et al. (2006) Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J Immunol 177 : 130–137.

39. KostopanagiotouG, AvgerinosE, CostopanagiotouC, ArkadopoulosN, AndreadouI, et al. (2008) Acute lung injury in a rat model of intestinal ischemia-reperfusion: the potential time depended role of phospholipases A(2). J Surg Res 147 : 108–116.

40. FrancoR, PachecoR, GatellJM, GallartT, LluisC (2007) Enzymatic and extraenzymatic role of adenosine deaminase 1 in T-cell-dendritic cell contacts and in alterations of the immune function. Crit Rev Immunol 27 : 495–509.

41. FischerJ, WestJ, AgochukwuN, SuireC, Hale-DonzeH (2007) Induction of host chemotactic response by Encephalitozoon spp. Infect Immun 75 : 1619–1625.

42. CastellinoF, HuangAY, Altan-BonnetG, StollS, ScheineckerC, et al. (2006) Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 440 : 890–895.

43. McKinneyC, MerrimanME, ChapmanPT, GowPJ, HarrisonAA, et al. (2008) Evidence for an influence of chemokine ligand 3-like 1 (CCL3L1) gene copy number on susceptibility to rheumatoid arthritis. Ann Rheum Dis 67 : 409–413.

44. BertiniR, LuiniW, SozzaniS, BottazziB, RuggieroP, et al. (1995) Identification of MIP-1 alpha/LD78 as a monocyte chemoattractant released by the HTLV-I-transformed cell line MT4. AIDS Res Hum Retroviruses 11 : 155–160.

45. ZlotnikA, YoshieO (2000) Chemokines: a new classification system and their role in immunity. Immunity 12 : 121–127.

46. RamadasRA, EwartSL, MedoffBD, LevineAM (2011) Interleukin-1 family member 9 stimulates chemokine production and neutrophil influx in mouse lungs. Am J Respir Cell Mol Biol 44 : 134–145.

47. CavaillonJM (1994) Cytokines and macrophages. Biomed Pharmacother 48 : 445–453.

48. AtzeniF, Sarzi-PuttiniP (2009) Anti-cytokine antibodies for rheumatic diseases. Curr Opin Investig Drugs 10 : 1204–1211.

49. MookherjeeN, BrownKL, BowdishDM, DoriaS, FalsafiR, et al. (2006) Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 176 : 2455–2464.

50. SabanR, D'AndreaMR, Andrade-GordonP, DerianCK, DozmorovI, et al. (2007) Regulatory network of inflammation downstream of proteinase-activated receptors. BMC Physiol 7 : 3–17.

51. ChenLC, ChenCC, LiangY, TsangNM, ChangYS, et al. (2011) A novel role for TNFAIP2: its correlation with invasion and metastasis in nasopharyngeal carcinoma. Mod Pathol 24 : 175–184.

52. LiuH, ChenA, GuoF, YuanL (2010) A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett 295 : 27–37.

53. RobertsonBW, BonsalL, ChellaiahMA (2010) Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells. Mol Cancer 9 : 260–269.

54. DelimpouraV, BakakosP, TseliouE, BessaV, HillasG, et al. (2010) Increased levels of osteopontin in sputum supernatant in severe refractory asthma. Thorax 65 : 782–786.

55. NauGJ, ChuppGL, EmileJF, JouanguyE, BermanJS, et al. (2000) Osteopontin expression correlates with clinical outcome in patients with mycobacterial infection. Am J Pathol 157 : 37–42.

56. ChangIF, HsiaoHY (2005) Induction of RhoGAP and pathological changes characteristic of Alzheimer's disease by UAHFEMF discharge in rat brain. Curr Alzheimer Res 2 : 559–569.

57. FestenEA, GoyetteP, GreenT, BoucherG, BeauchampC, et al. (2011) A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease. PLoS Genet 7: e1001283.

58. EyreS, HinksA, BowesJ, FlynnE, MartinP, et al. (2010) Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. Arthritis Res Ther 12: R175–R180.

59. MonteiroRC, Van De WinkelJG (2003) IgA Fc receptors. Annu Rev Immunol 21 : 177–204.

60. KnowlesHJ, te PoeleRH, WorkmanP, HarrisAL (2006) Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem Pharmacol 71 : 646–656.

61. ChoudharyD, JanssonI, StoilovI, SarfaraziM, SchenkmanJB (2004) Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos 32 : 840–847.

62. BirnbaumerM (2000) Vasopressin receptors. Trends Endocrinol Metab 11 : 406–410.

63. WangXJ, DysonMT, MondilloC, PatrignaniZ, PignataroO, et al. (2002) Interaction between arachidonic acid and cAMP signaling pathways enhances steroidogenesis and StAR gene expression in MA-10 Leydig tumor cells. Mol Cell Endocrinol 188 : 55–63.

64. WilliamsJP, WeiserMR, PechetTT, KobzikL, MooreFDJr, et al. (1997) alpha 1-Acid glycoprotein reduces local and remote injuries after intestinal ischemia in the rat. Am J Physiol 273: G1031–G1035.

65. SallenaveJM, CunninghamGA, JamesRM, McLachlanG, HaslettC (2003) Regulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafin. Infect Immun 71 : 3766–3774.

66. MoilanenM, SorsaT, StenmanM, NybergP, LindyO, et al. (2003) Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry 42 : 5414–5420.

67. KosakaT, YoshinoJ, InuiK, WakabayashiT, KobayashiT, et al. (2009) Involvement of NAD(P)H:quinone oxidoreductase 1 and superoxide dismutase polymorphisms in ulcerative colitis. DNA Cell Biol 28 : 625–631.

68. GaoB, FloresSC, LeffJA, BoseSK, McCordJM (2003) Synthesis and anti-inflammatory activity of a chimeric recombinant superoxide dismutase: SOD2/3. Am J Physiol Lung Cell Mol Physiol 284: L917–L925.

69. SubramaniamM, HawseJR, RajamannanNM, IngleJN, SpelsbergTC (2010) Functional role of KLF10 in multiple disease processes. Biofactors 36 : 8–18.

70. AnH, ChandraV, PirainoB, BorgesL, GeczyC, et al. (2010) Soluble LILRA3, a potential natural antiinflammatory protein, is increased in patients with rheumatoid arthritis and is tightly regulated by interleukin 10, tumor necrosis factor-alpha, and interferon-gamma. J Rheumatol 37 : 1596–1606.

71. SinghAK, StockP, AkbariO (2011) Role of PD-L1 and PD-L2 in allergic diseases and asthma. Allergy 66 : 155–162.

72. KellyLM, EnglmeierU, LafonI, SiewekeMH, GrafT (2000) MafB is an inducer of monocytic differentiation. EMBO J 19 : 1987–1997.

73. KimH, SeedB (2010) The transcription factor MafB antagonizes antiviral responses by blocking recruitment of coactivators to the transcription factor IRF3. Nat Immunol 11 : 743–750.